Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria-Victoria Mateos

Showing results (171-180 of 231) with videos related to

Pageof 24
Sort By:
Blood|September 6, 2019
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Albert Oriol, Rafael Rios, et al.
Blood Advances|September 29, 2021
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunologyCirino Botta, Catarina Maia, Juan-José Garcés, et al.
The Lancet. Oncology|May 31, 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy CommitteeYi Lin, Lugui Qiu, Saad Usmani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2025
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA StudySikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Journal for Immunotherapy of Cancer|March 6, 2026
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myelomaMagdalena Corona, Roberto García-Vicente, Adolfo Jesús Saez-Marin, et al.
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
American Journal of Hematology|April 7, 2022
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factorsAlessandro Gozzetti, Andrea Guarnieri, Elena Zamagni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
Blood Advances|May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONENizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
Pageof 24

Showing results (171-180 of 231) with videos related to

Sort By:
Pageof 24
Blood|September 6, 2019
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myelomaLaura Rosiñol, Albert Oriol, Rafael Rios, et al.
Blood Advances|September 29, 2021
FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunologyCirino Botta, Catarina Maia, Juan-José Garcés, et al.
The Lancet. Oncology|May 31, 2024
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy CommitteeYi Lin, Lugui Qiu, Saad Usmani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2025
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA StudySikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Journal for Immunotherapy of Cancer|March 6, 2026
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myelomaMagdalena Corona, Roberto García-Vicente, Adolfo Jesús Saez-Marin, et al.
The Lancet. Oncology|July 6, 2023
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios A Dimopoulos, Giampaolo Merlini, Frank Bridoux, et al.
American Journal of Hematology|April 7, 2022
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factorsAlessandro Gozzetti, Andrea Guarnieri, Elena Zamagni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
American Journal of Hematology|November 26, 2013
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched studyFortunato Morabito, Sara Bringhen, Alessandra Larocca, et al.
Blood Advances|May 5, 2026
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONENizar J Bahlis, Thierry Facon, Jesús F San-Miguel, et al.
Pageof 24